These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 21844324)

  • 1. Anidulafungin in treatment of experimental invasive infection by Candida parapsilosis: in vitro activity, (1-->3)-beta-D-glucan and mannan serum levels, histopathological findings, and in vivo efficacy.
    Salas V; Pastor FJ; Calvo E; Mayayo E; Quindós G; Carrillo AJ; Guarro J
    Antimicrob Agents Chemother; 2011 Nov; 55(11):4985-9. PubMed ID: 21844324
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of the correlation of caspofungin MICs and treatment outcome in murine infections by wild type strains of Candida parapsilosis.
    Salas V; Pastor FJ; Capilla J; Sutton DA; Mayayo E; Fothergill AW; Rinaldi MG; Guarro J
    Diagn Microbiol Infect Dis; 2013 Sep; 77(1):41-5. PubMed ID: 23806662
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro and in vivo effects of echinocandins against Candida parapsilosis sensu stricto, Candida orthopsilosis and Candida metapsilosis.
    Spreghini E; Orlando F; Tavanti A; Senesi S; Giannini D; Manso E; Barchiesi F
    J Antimicrob Chemother; 2012 Sep; 67(9):2195-202. PubMed ID: 22635526
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activity of anidulafungin in a murine model of Candida krusei infection: evaluation of mortality and disease burden by quantitative tissue cultures and measurement of serum (1,3)-beta-D-glucan levels.
    Ostrosky-Zeichner L; Paetznick VL; Rodriguez J; Chen E; Sheehan DJ
    Antimicrob Agents Chemother; 2009 Apr; 53(4):1639-41. PubMed ID: 19139291
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anidulafungin versus caspofungin in a mouse model of candidiasis caused by anidulafungin-susceptible Candida parapsilosis isolates with different degrees of caspofungin susceptibility.
    Dimopoulou D; Hamilos G; Tzardi M; Lewis RE; Samonis G; Kontoyiannis DP
    Antimicrob Agents Chemother; 2014; 58(1):229-36. PubMed ID: 24145540
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Echinocandin antifungal drugs in fungal infections: a comparison.
    Chen SC; Slavin MA; Sorrell TC
    Drugs; 2011 Jan; 71(1):11-41. PubMed ID: 21175238
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model.
    Andes D; Diekema DJ; Pfaller MA; Prince RA; Marchillo K; Ashbeck J; Hou J
    Antimicrob Agents Chemother; 2008 Feb; 52(2):539-50. PubMed ID: 18070979
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro activity and in vivo efficacy of anidulafungin in murine infections by Aspergillus flavus.
    Calvo E; Pastor FJ; Mayayo E; Salas V; Guarro J
    Antimicrob Agents Chemother; 2011 Mar; 55(3):1290-2. PubMed ID: 21149624
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapies against murine Candida guilliermondii infection, relationship between in vitro antifungal pharmacodynamics and outcome.
    Paredes K; Pastor FJ; Capilla J; Sutton DA; Mayayo E; Fothergill AW; Guarro J
    Rev Iberoam Micol; 2015; 32(1):34-9. PubMed ID: 24594291
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of anidulafungin in the treatment of experimental Candida parapsilosis catheter infection using an antifungal-lock technique.
    Basas J; Morer A; Ratia C; Martín MT; Del Pozo JL; Gomis X; Rojo-Molinero E; Torrents E; Almirante B; Gavaldà J
    J Antimicrob Chemother; 2016 Oct; 71(10):2895-901. PubMed ID: 27378814
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Candida and candidaemia. Susceptibility and epidemiology.
    Arendrup MC
    Dan Med J; 2013 Nov; 60(11):B4698. PubMed ID: 24192246
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical breakpoints for the echinocandins and Candida revisited: integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria.
    Pfaller MA; Diekema DJ; Andes D; Arendrup MC; Brown SD; Lockhart SR; Motyl M; Perlin DS;
    Drug Resist Updat; 2011 Jun; 14(3):164-76. PubMed ID: 21353623
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative in vitro susceptibility of clinical isolates of Candida paparsilosis complex and other Candida species to caspofungin and anidulafungin by Etest.
    Khan Z; Ahmad S; Joseph L; Chandy R; Theyyathel A
    J Chemother; 2011 Apr; 23(2):97-101. PubMed ID: 21571626
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro antifungal activities and in vivo efficacies of 1,3-beta-D-glucan synthesis inhibitors L-671,329, L-646,991, tetrahydroechinocandin B, and L-687,781, a papulacandin.
    Bartizal K; Abruzzo G; Trainor C; Krupa D; Nollstadt K; Schmatz D; Schwartz R; Hammond M; Balkovec J; Vanmiddlesworth F
    Antimicrob Agents Chemother; 1992 Aug; 36(8):1648-57. PubMed ID: 1416847
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EUCAST Reference Testing of Rezafungin Susceptibility and Impact of Choice of Plastic Plates.
    Arendrup MC; Jørgensen KM; Hare RK; Cuenca-Estrella M; Zaragoza O
    Antimicrob Agents Chemother; 2019 Sep; 63(9):. PubMed ID: 31285230
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of anidulafungin against Aspergillus niger in vitro and in vivo.
    Calvo E; Pastor FJ; Mayayo E; Guarro J
    Int J Antimicrob Agents; 2011 Oct; 38(4):360-3. PubMed ID: 21824751
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antifungal therapies in murine infections by Candida kefyr.
    Sanchis M; Martin-Vicente A; Capilla J; Guarro J
    Mycoses; 2016 Apr; 59(4):253-258. PubMed ID: 26857550
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation of MIC with outcome for Candida species tested against caspofungin, anidulafungin, and micafungin: analysis and proposal for interpretive MIC breakpoints.
    Pfaller MA; Diekema DJ; Ostrosky-Zeichner L; Rex JH; Alexander BD; Andes D; Brown SD; Chaturvedi V; Ghannoum MA; Knapp CC; Sheehan DJ; Walsh TJ
    J Clin Microbiol; 2008 Aug; 46(8):2620-9. PubMed ID: 18579718
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro potency and fungicidal activity of CD101, a novel echinocandin, against recent clinical isolates of Candida spp.
    Hall D; Bonifas R; Stapert L; Thwaites M; Shinabarger DL; Pillar CM
    Diagn Microbiol Infect Dis; 2017 Nov; 89(3):205-211. PubMed ID: 28826987
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anidulafungin is fungicidal and exerts a variety of postantifungal effects against Candida albicans, C. glabrata, C. parapsilosis, and C. krusei isolates.
    Nguyen KT; Ta P; Hoang BT; Cheng S; Hao B; Nguyen MH; Clancy CJ
    Antimicrob Agents Chemother; 2009 Aug; 53(8):3347-52. PubMed ID: 19364856
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.